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A b s t r a c t  
The aim of the present investigation was to development of immediate release liquid coated pellets 
of poorly soluble drugs Amlodipine besylate (AMD) and Nebivolol HCl (NBV) by novel liquid layering 
technology to enhance solubility and bioavailability with HPC-EF as hydrophilic polymer and PVP K 
30 as binder. 
A 32 full factorial design was employed to optimize the formulation of pellets. In order to optimize 
formulations, two polymers HPC-EF and PVP K 30 as factors and amount of polymers (three 
different concentrations), were taken as independent variables. All the formulations were evaluated 
for particle size, friability, moisture content, drug content, in vitro dissolution studies and in vivo 
bioavailability studies. 
All the formulations were found uniform with respect to all evaluation parameters. The optimized 
formulation (F5) showed highest % of drug release 99.59 by the end of 8 min for AMD and 99.21 % 
of drug release for NBV, when compared with the marketed product (NEBISTAR-AM) the 
percentage of AMD and NBV was 83.91 and 82.67 respectively within 8 min, by using 4% of HPC-
EF and 1% of PVP K 30. SEM confirmed that F5 was spherical in shape with a smooth surface.  
In vivo studies indicated significant difference in the bioavailability between AMD and NBV coated 
pellets with pure drug. Clinical data confirmed that the optimized formulation (F5) by choosing 
immediate release drug coated pellet technology by liquid layering method could improve patient 
compliance and ensure better disease management when compared with the marketed product. 
Keywords: Amlodipine besylate, Nebivolol HCl, pellets, liquid layering technique,bioavailability 
studies.
Introduction 
With the advances in pharmaceutical research, there are 
thousands of new compounds getting synthesized every year and 
out of these, 40% show solubility problem which further makes 
their processing difficult. Poor aqueous solubility not only produces 
irreproducible therapeutic response but also leads to the wastage 
of large amount of drugs [1, 2].  
These molecules are difficult to formulate using conventional 
approaches and are associated with innumerable formulation-
related performance issues [3]. Multiparticulate dosage forms are 
receiving an immense attention as alternative drug delivery 
systems for oral drug delivery even though single-unit dosage 
forms have been widely used for decades [4]. Pellets are 
agglomerates of fine powders or granules of bulk drugs and 
excipients [5]. Pellets have free flowing properties and low porosity 
of about 10% [6]. Experimental designs have long been employed 
to optimize various industrial products and/or processes such as 
the factorial designs (FDs) since 1926 [7]. Amlodipine besylate is a 
calcium channel blocker can reduces blood pressure by dilate 
blood vessel leads to reduction of cardiac output and slowing heart 
rate [8]. Nebivolol is a long acting, cardio selective beta blockers, 
currently licensed for the treatment of hypertension [9]. The aim 
of the present investigation was to develop a multiparticulate 
dosage form containing amlodipine besylate and nebivolol 
hydrochloride drug layered pellets with the objective of 
enhancing the solubility and bioavailability of the drug by using 
liquid layering technology. 
Materials and Methods 
Nebistar-AM (2.5mg Amlodipine besylate & Nebivolol HCl 5mg) 
was purchased from Lupin Pharma, Mumbai. Amlodipine besylate 
and Nebivolol hydrochloride was gifted by Aurobindo pharma 
limited, Hyderabad, India. PVP K 30, Hydroxy Propyl Cellulose 
HPC-EF and MCC were obtained from MSN laboratories, 
Hyderabad. All other polymers and solvents used were of 
analytical grade. 
Procedure for the preparation of core pellets 
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Preparation of core pellets 
Weighed accurately 44g of MCC and pass through #30/#40 mesh, 
to this add binder solution prepared by taking 0.05 g of PVP K 30 
dissolved in water and mixed thoroughly. The sugar solution is 
sprayed on to the prepared beads, dried the pellets at 450 and 
again passed through the sieve #20 mesh and used for seal 
coating. 
Coating of polymer solution 
Weighed 50g of core pellets and different concentrations of 
polymeric solution of HPC-EF (3%, 4%, 5%) was sprayed on to the 
core pellets by maintain the coating pan rotating at a speed of 
45rpm and hot air (70oC) is passed simultaneously through the pan 
to dry the coated pellets. 
Coating of drug solution on to sub-coated pellets 
Prepared different concentrations of PVP K 30 by dissolving 0.5g, 
1g, 1.5g of PVP K 30 in water and added to the beaker containing 
drugs Amlodipine besylate and Nebivolol HCl with methanol. The 
prepared solution was sprayed on to the sub coated pellets through 
spray gun at a rate of a 2ml/min, maintain the coating pan speed of 
45 rpm and follow the process as mentioned in coating of polymer 
solution. The compositions of Amlodipine & Nebivolol solution with 
polymers coated on core pellets are summarized in Table 1. 
 
Table 1: Composition of Amlodipine & Nebivolol solution with polymers coated on core pellets 
S.NO FORMU-
LATION 
CORE 
PELLETS (g) 
AMLODIPINE 
BESYLATE (g) 
NEBIVOLOL HYDRO-
CHLORIDE(g) 
HPC-
EF (g) 
PVP K30 
(g) 
METHANOL (ml)
1 F1 50 1.25 2.5 2.5 0.5 20
2 F2 50 1.25 2.5 2.5 1.5 20
3 F3 50 1.25 2.5 1.5 1.5 20
4 F4 50 1.25 2.5 2 1.5 20
5 F5 50 1.25 2.5 2 0.5 20
6 F6 50 1.25 2.5 1.5 0.5 20
7 F7 50 1.25 2.5 2.5 1 20
8 F8 50 1.25 2.5 2 1 20
9 F9 50 1.25 2.5 2 1 20
10 F10 50 1.25 2.5 1.5 1 20
 
Experimental design and statistical analysis 
In this study, a 32 full factorial design was employed to optimize the 
formulation of pellets. In order to optimize formulations, two 
polymers HPC EF and PVP K 30 as factors and amount of 
polymers (three different concentrations), were taken as 
independent variables. HPC-EF, being hydrophilic is more 
permeable to water so it promotes release of drug. PVP K 30 is 
also hydrophilic and acts as a binder and viscosity enhancer. 
Selection of response variables was crucial. The target was to 
obtain the drug release immediately, but simultaneously to achieve 
the maximum release. Therefore the response variables selected 
for evaluation of immediate release were percent of drug release 
within 2min and 8min was selected as dependent variables. The 
data obtained by experimental design was processed using Design 
expert 9.0.1.0 software. 3-D response surface curves were 
constructed to study the effect of three independent variables alone 
and in combination of percent drug release at 2min and 8min. All 
the responses observed were simultaneously fitted to quadratic 
models and were evaluated in terms of statistical parameters.  
Evaluation parameters 
Particle size analysis 
The particle size of the pellets was measured by using projected 
area diameter.  It is the diameter of a circle having the same area 
as the particle viewed normally to the plane surface on which the 
particle is at rest in a stable position [10].  
Friability 
Roche friability tester (Electrolab friability tester, EF-2, India) was 
used to determine the friability. Pre-weighed pellets were placed in 
friabilator and rotated at a speed of 25rpm for 4 min. The friability 
was calculated using the following equation [11]. 
Friability (%) = [1ă initial weight / weight retained after 100 
rotations] ï 100  
Moisture content 
1g of pellets were weighed and kept in oven at 40oC. Its weight 
was noted as initial weight (W1). They were removed from the 
oven after regular intervals of 15min and weighed. Loss in weight 
of pellets was noted. After attaining constant weight, it was noted 
as final weight (W2) and percent moisture content was calculated 
[12]. 
Drug content 
115mg of drug layered pellets was taken and crushed to a find 
powder. The powdered material was transferred in to a 100 ml 
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volumetric flask and pH 1.2 HCl buffer was added to it. It was 
continuously stirred for 2 hrs. About 10 ml of the solution was taken 
from the volumetric flask and centrifuged. The solution from the 
centrifuge tube was filtered by using Millipore filter. Then the filtrate 
was subsequently diluted and the absorbance was measured at 
238nm and 280nm for Amlodipine besylate and Nebivolol HCl 
respectively [13].  
In vitro drug release studies 
Pellets equivalent to 2.5mg Amlodipine besylate and 5mg Nebivolol 
hydrochloride were weighed and placed in 900 ml of dissolution 
media (pH-1.2 HCl buffer) containing in USP dissolution apparatus 
II and stirred at a speed of 75 rpm at 37μ0.5oC. 5ml of aliquots 
were withdrawn at 1, 2, 4, 6, 8 min and replaced by 5 ml of fresh 
dissolution media. The collected samples are measured at three 
wavelengths such as 238nm, 268nm (Iso-absorptive point) and 
280nm. The amount of drug released was calculated from the 
calibration curve of the same dissolution medium. 
Scanning Electron Microscopy (SEM) 
The surface and shape characteristics of pellets were determined 
by scanning electron microscopy (SEM). Photographs were taken 
and recorded at suitable magnification. 
Stability studies 
The stability study of the formulated drug layered pellets was 
carried out under different conditions according to ICH guidelines. 
The drug layered pellets were stored in a stability chamber for 
stability studies. Accelerated Stability studies were carried out at 40 
0C / 75 % RH for the best formulations for 3 months. The drug 
layered pellets were characterized for the drug content and other 
parameters during the stability study period [14].  
In vivo studie 
Animal Preparation  
Eighteen healthy male rats were selected for this study, all the 
animals were healthy during the period of the experiment. All 
efforts were made to maintain the animals under controlled 
environmental conditions (Temperature 250C, Relative Humidity 
45% and 12 h alternate light and dark cycle] with 100 % fresh air 
exchange in animal rooms, uninterrupted power and water supply 
and rats were fed with standard diet and water ad libitum. The 
protocol of animal study was approved by the institutional animal 
ethics committee (IAEC NO: IAEC / SUCP/07/2013). The rats were 
fasted overnight before administration of the formulation 
(Amlodipine Besylate, Nebivolol Hydrochloride coated pellets) and 
pure drug (Amlodipine Besylate, Nebivolol Hydrochloride). The rats 
were randomly divided into two groups each group contains six 
animals. The group A rats were received prepared Amlodipine 
Besylate, Nebivolol Hydrochloride coated pellets, group B received 
pure drug Amlodipine Besylate, and group C received Nebivolol 
Hydrochloride pure drug administered orally.  
Blood samples for pharmacokinetic analysis were obtained at 
different time intervals 0, 15, 30, 60, 120, 240, 360 min and 24hrs 
after dosing. Blood samples were collected in heparinized tubes 
and were centrifuged for 10min at 3,000 rpm at room temperature 
[15]. 
Preparation of Plasma Samples for HPLC Analysis  
Rat plasma (0.5 ml) was prepared for chromatography by 
precipitating proteins with 2.5 ml of ice-cold absolute ethanol for 
each 0.5 ml of plasma. After centrifugation the ethanol was 
transferred into a clean tube. The precipitate was resuspended with 
1 ml of acetonitrile by vortexing for 1 min. After centrifugation (5000 
ă 6000 rpm for 10 min), the acetonitrile was added to the ethanol 
and the organic mixture was taken to near dryness by a steam of 
nitrogen at room temperature. Samples were reconstituted in 200 
μ1 of Mobile phase was injected for HPLC analysis. 
Hydrochlorothiazide was added as internal standard. The 
chromatographic conditions were shown in Table 2. 
 
Table 2: Chromatographic conditions   
Column C18
Mobile Phase Acetonitrile : Phosphate buffer (PH 3.0) 
(40:60) 
Flow rate 0.8ml/min 
Injection volume 20øl
Retention times Hydrochlorothiazide (Internal standard) -
2.643 Amlodipine besylate - 6.393, 
Nebivolol HCl -11.342 
Results and Discussion 
Evaluation Parameters 
Particle size analysis 
Each pellet size was measured by using electron microscope and 
found to be 735-770 øm.  
The drug layered pellets were also evaluated for friability and 
moisture content, which found to be within the Indian 
Pharmacopoeal limits.  
Drug content 
All the formulations of Amlodipine besylate and Nebivolol HCl 
coated pellets were found to contain an almost uniform quantity of 
the drug, as per content uniformity studies indicating reproducibility 
of the technique. Drug content in the all formulations were 
evaluated and the values of Amlodipine besylate and Nebivolol HCl 
were found to be between 98.58 μ 0.15 to 99.82 μ 0.55 & 98.34 μ 
0.52 to 99.67 μ 0.52 respectively. As per the USP requirements, 
the formulations were found to meet the criteria for content 
uniformity, results are depicted in Table  
4. 
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Table 4:  % Drug content of Amlodipine besylate and Nebivolol 
hydrochloride coated pellets 
FORMULATIO
N CODE 
AMLODIPIN
E 
BESYLATE 
NEBIVOLOL 
HYDROCHLORID
E 
F1 99.54 μ 025 98.92 μ 0.31 
F2 98.91 μ 0.64 99.27 μ 0.39 
F3 98.58 μ 0.15 98.69 μ 0.53 
F4 99.72 μ 0.52 98.73 μ 0.39 
F5 99.16 μ 0.34 99.67 μ 0.52 
F6 99.60 μ 0.39 98.82 μ 0.47 
F7 99.53 μ 0.46 98.80 μ 0.39 
F8 99.82 μ 0.55 99.10 μ 0.43 
F9 99.29 μ 0.43 98.34 μ 0.52 
F10 99.04 μ 0.41 98.86 μ 0.48 
 
In vitro drug release studies 
The % drug release of Amlodipine besylate from formulations F1 to 
F10 are within the range of 77.49 μ 0.48 to 99.59 μ 0.40 at the end 
of 8 min.  Rapid drug dissolution was observed in F5 as 99.59. The 
% drug release of Nebivolol HCl from formulations F1 to F10 are 
within the range of 77.49 μ 0.48 to 99.21 μ 0.29 at the end of 8 
min.  Rapid drug dissolution was observed in F5 as 99.21. The 
optimized formulation (F5) shows highest percent of drug release 
99.59 by the end of 8 min for Amlodipine besylate (Table 5) (Figure 
1) and 99.21 % of drug release for Nebivolol HCl (Table 6) (Figure 
3), when compared with the marketed product (NEBISTAR-AM) the 
% of Amlodipine besylate (Figure 2) and Nebivolol HCl (Figure 4) 
was 83.91 μ 0.21 and 82.67 μ 0.26 respectively within 8 min.  
 
 
Table 5: Cumulative % drug release of pellets coated with Amlodipine besylate 
FORMULATION CODE 0 min 1min 2min 4min 6min 8min 
F1 0 60.24 μ 0.29 80.61 μ 0.57 83.27 μ 0.34 86.59 μ 0.46 92.21 μ 0.42
F2 0 56.24 μ 0.54 75.85 μ 0.51 78.51 μ 0.43 81.37 μ 0.46 88.16 μ 0.38
F3 0 49.61 μ 0.18 65.58 μ 0.28 68.71 μ 0.43 70.58 μ 0.38 72.19 μ 0.25
F4 0 69.51 μ 0.27 83.91 μ 0.29 87.12 μ 0.42 91.37 μ 0.31 95.36 μ 0.27
F5 0 71.52 μ 0.39 85.92 μ 0.41 93.17 μ 0.60 96.51 μ 0.27 99.59 μ 0.40
F6 0 53.27 μ 0.61 69.37 μ 0.28 72.12 μ 0.57 75.13 μ 0.19 80.40 μ 0.35
F7 0 61.19 μ 0.31 78.17 μ 0.72 80.56 μ 0.51 83.12 μ 0.38 86.26 μ 0.39
F8 0 70.01 μ 0.47 83.97 μ 0.61 92.09μ 0.43 95.53 μ 0.41 97.85 μ 0.31
F9 0 69.51 μ 0.29 83.62 μ 0.61 91.13μ 0.43 94.83 μ 0.41 97.03 μ 0.31
F10 0 51.57 μ 0.49 68.10 μ 0.38 70.15 μ 0.37 73.29 μ 0.58 78.58 μ 0.42
NEBISTAR-AM 0 62.72 μ 0.34 68.92 μ 0.24 74.10 μ 0.17 78.26 μ 0.27 83.91 μ 0.21
 
Table 6: Cumulative % drug release of pellets coated with Nebivolol hydrochloride 
FORMULATION 0 min 1min 2min 4min 6min 8min
F1 0 72.74 μ 0.27 80.04 μ 0.49 83.91 μ 0.37 86.54 μ 0.54 92.05 μ 0.49
F2 0 67.51 μ 0.34 74.12 μ 0.37 78.91 μ 0.49 81.57 μ 0.74 88.13 μ 0.49
F3 0 59.10 μ 0.48 65.09 μ 0.51 68.19 μ 0.27 70.01 μ 0.38 71.91 μ 0.54
F4 0 76.91 μ 0.17 81.12 μ 0.43 86.59 μ 0.61 91.02 μ 0.27 95.91 μ 0.37
F5 0 71.82 μ 0.32 85.19 μ 0.72 93.88 μ 0.31 96.06 μ 0.67 99.21 μ 0.29
F6 0 60.87 μ 0.61 68.74 μ 0.29 71.67 μ 0.38 74.91 μ 0.56 80.01 μ 0.37
F7 0 69.69 μ 0.11 78.05 μ 0.51 81.62 μ 0.49 83.71 μ 0.28 89.41 μ 0.34
F8 0 79.57 μ 0.17 83.91 μ 0.46 90.69 μ 0.27 94.53 μ 0.51 97.21 μ 0.24
F9 0 79.11 μ 0.39 83.24 μ 0.46 90.69 μ 0.27 94.53 μ 0.51 96.72 μ 0.24
F10 0 60.97 μ 0.29 67.72 μ 0.72 69.79μ 0.61 72.19 μ 0.37 77.49 μ 0.48
NEBISTAR-AM 0 62.72 μ 0.34 68.15 μ 0.24 73.49 μ 0.18 77.09 μ 0.21 82.67 μ 0.26
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Figure 1: In-vitro release of amlodipine besylate in coated pellets and marketed product. 
 
 
 
 
Figure 2: Comparision of cumulative % drug release of Amlodipine besylate of prepared formulation (F5) with marketed product NEBISTAR-AM 
 
 
 
 
 
 
0
20
40
60
80
100
120
0 5 10C
um
ul
at
iv
e 
%
 d
ru
g 
re
le
as
e
Time (min)
F1
F2
F3
F4
F5
F6
F7
F8
F9
0
20
40
60
80
100
120
0 5 10
C
um
ul
at
iv
e 
%
 d
ru
g 
re
le
as
e
Time (min) 
F5
NEBISTAR-
AM
0
20
40
60
80
100
120
0 5 10C
um
ul
at
iv
e 
%
 d
ru
g 
re
le
as
e
Time (min)
F1
F2
F3
F4
F5
F6
F7
F8
Rani et al. International Journal of Drug Delivery 6 (3) 254-267 [2014] 
 
 
  
PAGE | 259 |
 
Figure 3: In-vitro release of Nebivolol hydrochloride in coated pellets and  marketed Product 
 
 
Figure 4: Comparision of cumulative % drug release of Nebivolol hydrochloride of prepared formulation (F5) 
with marketed product NEBISTAR-AM
Scanning Electron Microscopy 
The Amlodipine & Nebivolol HCl coated optimized pellet 
formulation (F5) was characterized by SEM analysis to understand 
the pellet shape and surface morphology (Figure 15 & 16). The 
pellets prepared were having spherical in shape and smooth 
surface with minimal pores, indicating the uniform coating of the 
pellets.
 
 
Figure 5: SEM images of Amlodipine & Nebivolol HCl coated pellets 
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Figure 6: SEM images of Amlodipine & Nebivolol HCl coated pellets 
 
Stability Studies for Amlodipine & Nebivolol HCl coated 
optimized pellet formulation (F5) 
F5 formulation was selected for stability studies on the basis of 
excellent % drug content & high cumulative % drug release of 
Amlodipine & Nebivolol HCl from pellets. Stability studies were 
conducted under accelerated conditions according to ICH 
guidelines using Remi stability chambers, Mumbai. From these 
results it was concluded that, formulation F5 was stable and 
retained their original properties with minor differences (Table 7).  
 
Table 7: Accelerated stability testing data of optimized formulation (F5) at 40 ÀC/75 %RH  
           
Retest Time For F5 
Percent Drug Content/ 
Assay for Amlodipine 
besylate (%) 
Cumulative % drug 
release for Amlodipine 
besylate 
Percent Drug Content/ 
Assay for Nebivolol 
HCl (%) 
Cumulative % drug 
release for Nebivolol 
HCl 
1 Week 99.15 99.45 99.65 99.00 
2 Weeks 98.85 98.55 98.95 98.45 
1 Month 98.22 98.32 98.42 98.12 
2 Months 98.05 98.00 98.15 97.80 
3 Months 97.60 97.30 97.50 97.20 
 
Experimental design and statistical analysis 
The experiments were designed to study effect of two independent 
variables at three levels on response variables such as percent 
drug release at 2min and 8min. The counter plot will help in 
understanding of the design space. In all the above counter plots 
the design space is available in the red color region which is 
indicated in the plot as shaded region from 3.5-4.75% of HPC-EF 
concentration, so this is the space we should focus on, to obtain 
the formulation with accurate results. The immediate release of 
amlodipine besylate and nebivolol hydrochloride was observed at 
the 4% concentration of HPC-EF and 1% of PVP K 30.  
Statistical models 
For % release response, F-value, P-value, R Square and adequate 
precision of amlodipine besylate and nebivolol at 2min and 8min 
were shown in Table 8 & 9. From F-values & P-values, the model 
is significant. Adequate precision shows signal to noise ratio. The 
ratio of amlodipine besylate and nebivolol hydrochloride indicates 
an adequate signal, thus the proposed model can be used to 
navigate the design space. 
 
Table 8: ANOVA of dependant variables for Amlodipine besylate 
Response 
model 
F value P value R Square Adequate 
Precision 
2min 1654.20 <0.0001 0.9995 104.95
8min 181.32 <0.0001 0.9956 37.468
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Table 9: ANOVA of dependant variables for Nebivolol HCl 
Response 
model 
F value P value R Square Adequate 
Precision 
2min 2068.83 <0.0001 0.9996 117.85
8min 131.83 <0.0001 0.9940 31.787
Response surface analysis 
A substantial high drug release is achieved in F5 formulation which 
is very much faster than the marketed product (Nebistar-AM). The 
statistical analysis of the factorial design batches was performed by 
multiple linear regression analysis. The t2, t8 values for the 10 
batches showed a wide variation. The values of the correlation 
coefficient indicate a good fit. The polynomial equation can be used 
to draw conclusions after considering the magnitude of coefficient 
and the mathematical sign it carries, (i.e. positive or negative).  
From figure 17 the plots were found to be linear for 70%, 75%, 
80% and 85% dissolution rate which is found between 3-3.75% of 
polymer concentration, but there is a non linearity for 90% around 
4% concentration of polymer in figure 17 and figure 19 for 
Amlodipine besylate. In figure 18 and figure 20 at 80% and 90% 
the linear nature is observed, the plot shows nonlinear nature at 
100% dissolution rates.  
Response surface plots are very helpful in learning about both the 
main and interaction effects of the independent variables.  From 
the above 3D-surface graphs, the observation noted is that the, 
release of drug increased to a great extent when the concentration 
of polymer is increased from 3% to 4% for Amlodipine besylate 
(figure 21 and figure 23) and for Nebivolol hydrochloride (figure 22 
and figure 24) but very minor effect of PVP K 30 is observed in the 
release profile of drug, because even the PVP K 30 concentration 
is increased the residual surface towards the factor B is altered to a 
little extent at the end of 8min, but this is not showing a remarkable 
difference. So from the above plot we can confirm that the release 
of drug at 8min is also due to the HPC-EF polymer only. The 
amlodipine besylate and nebivolol hydrochloride released into the 
fluid is mainly depending on the variation in the polymer 
concentration but not on the variation in binder concentration.  
The F5 formulation is checked for its drug release in 6 trials and 
each trial is performed for 3 times to avoid the variance in the 
release profile of the drug. The variance is very less as 0.0157 and 
the critical F value (2.2718) is greater than calculated F value 
(1.2336) for amlodipine besylate and the variance for nebivolol 
hydrochloride is 0.0235 and the critical F value (2.2724) is greater 
than calculated F value (1.1145), which says that the repeatability 
of the release of the drug is high. The critical F value is greater 
than the calculated F value, so it is confirmed that the F5 
formulation is selected as the best formulation among the ten 
prepared formulations. 
 
 
Figure 7: Counter plot showing the influence of amount of polymer and amount of binder on the release 
profile of Amlodipine besylate after 2min 
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Figure 8: Response surface plot showing the influence of amount of polymer and amount of binder on 
the release profile of Amlodipine besylate after 2min 
 
 
Figure 9: Counter plot showing the influence of amount of polymer and amount of binder on the release 
profile of Amlodipine besylate after 8min 
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Figure 10: Response surface plot showing the influence of amount of polymer and amount of binder on 
the release profile of Amlodipine besylate after 8min 
 
 
Figure 11: Counter plot showing the influence of amount of polymer and amount of binder on 
the release profile of Nebivolol hydrochloride after 2min 
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Figure 12: Response surface plot showing the influence of amount of polymer and amount of binder on 
the release profile of Nebivolol hydrochloride after 2min 
 
 
Figure 13: Counter plot showing the influence of amount of polymer and amount of binder on the release 
profile of Nebivolol hydrochloride after 8min 
Rani et al. International Journal of Drug Delivery 6 (3) 254-267 [2014] 
 
 
  
PAGE | 265 |
 
 
Figure 14: Response surface plot showing the influence of amount of polymer and amount of binder 
on the release profile of Nebivolol hydrochloride after 8min 
 
 
In vivo studies 
Bioavailability Parameters 
Pharmacokinetic studies were carried out for test formulation (F5) 
(coated with AMD and NBV) and pure drugs, where results are 
shown in Table 13 for AMD and Table 14 for NBV. The Cmax and 
Tmax for test formulation for AMD and Amlodipine pure drug was 
found to be 1050μ24 øg/ml, 15μ22h and 950μ32øg/ml and 30μ15h 
respectively. In order to estimate the amount of drug absorbed 
from the test formulation, the relative bioavailability was calculated 
from the AUC of the pure drug and test formulation 
(17006μ045øg.hr/ml and 18789μ735øg.hr/ml). The above results 
indicated that the bioavailability of the test formulation was 
increased significantly compare with pure drug. The t1/2 for 
optimized test formulation and pure drug was 1.005μ0.142h and 
1.263μ0.213h, respectively. The Cmax and Tmax for test formulation 
for NBV and Nebivolol pure drug was found to be 2152μ125 øg/ml, 
15μ42h and 2001μ243øg/ml and 30μ35h respectively. In order to 
estimate the amount of drug absorbed from the test formulation, 
the relative bioavailability was calculated from the AUC of the pure 
drug and test formulation (802721μ32øg.hr/ml and 
8630128μ25øg.hr/ml). The above results indicated that the 
bioavailability of the test formulation was increased significantly 
compare with pure drug. The t1/2 for optimized test formulation and 
pure drug was 1.135μ0.142h and 1.253μ0.213h, respectively.  
 
Table 13: Comparison of pharmacokinetic parameters of 
Amlodipine besylate coated pellets and Pure Amlodipine besylate 
in Rats (Mean μ SD, n = 6). 
Parameters 
 
Test 
formulation(F5) 
PureAmlodipine 
besylate 
Dose (mg/kg) 2.5 2.5
Cmax (øg /ml) 1050μ24 950μ32
AUC 0-t (øg.hr/ml) 17678μ745 15995μ055
AUC 0-inf (øg.hr/ml) 18789μ735 17006μ045
Tmax (Min) 15μ22 30μ15
t 1/2 (h) 1.005μ0.142 1.263μ0.213
K el (h-1) 0.293μ0.23 0.246μ0.42
 
Table 15: Comparison of pharmacokinetic parameters of Nebivolol 
hydrochloride coated pellets and Pure Nebivolol hydrochloride in 
rat (Mean μ SD, n = 6). 
Parameters 
 
Test formulation 
(F5) 
Pure Nebivolol 
hydrochloride 
Dose (mg/kg) 5 5
Cmax ((øg /ml) 2152μ125 2001μ243
AUC 0-t (øg.hr/ml) 8430137μ2 783861μ73
AUC 0-inf (øg.hr/ml) 8630128μ25 802721μ32
Tmax (Min) 15μ42 30μ35
t 1/2 (h) 1.135μ0.142 1.253μ0.213
K el (h-1) 0.392μ0.33 0.296μ0.42
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Conclusion 
In this work, systematic studies were conducted on drug (AMD and 
NBV) coated pellets, prepared by using 3
2 
full factorial design 
optimize the formulation of pellets using  HPC-EF as hydrophilic 
polymer and PVP K 30 as binder. In order to optimize formulations, 
two polymers HPC-EF and PVP K 30 as factors and amount of 
polymers (three different concentrations), were taken as 
independent variables. The drug coated pellets were evaluated for 
bulk density, tapped density, HausnerÊs ratio, CarrÊs index and 
angle of repose, % yield of pellets, drug content, drug loading 
efficiency, moisture content and friability and found to be within the 
Indian Pharmacopoeal limits. Based on the physicochemical 
properties, evaluation parameters and in vitro dissolution studies, it 
was concluded that F5 finalized as optimized formulation. By using 
the factorial design with 4% of HPC-EF and 1% of PVP K 30 we 
could achieve a maximum drug release of 99.59μ 0.40 and 99.21μ 
0.29 by the end of 8 min for Amlodipine besylate and Nebivolol HCl 
respectively, when compared with the marketed product 
(NEBISTAR-AM) the % of Amlodipine besylate and Nebivolol HCl 
was 83.91 μ 0.21 and 82.67 μ 0.26 within 8 min. From the above 
results we can conclude that the release of the drug from the 
pellets is depended on the concentration of the HPC-EF but very 
minute effect is observed with PVP K 30. The optimized 
formulation (F5) was characterized by SEM analysis to find out the 
pellet shape and surface morphology and found to be spherical in 
shape and smooth surface with minimal pores, indicating the 
uniform coating of the pellets. The comparison of in vivo 
bioavailability studies of the Amlodipine besylate and Nebivolol 
hydrochloride coated pellets and that of a pure drugs confirmed 
that the drug coated pellets shown immediate release and 
increased oral bioavailability.  
Therefore, the present AMD and NBV coated pellets are 
considered to be potentially useful for the treatment where 
improved patient compliance and convenience is expected. 
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